Skip to main content

Table 2 Outcomes of macular HEs following IVR therapy

From: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

 

One month

Three month

P-value

n

288

288

 

2-grade reduction

69 (23.9%)

155 (53.8%)

0.000***

No change in the area

143 (49.6%)

90 (31.2%)

0.001**

2-grade enlargement

76 (26.3%)

43 (14.9%)

0.000***

  1. IVR Intravitreal injections of ranibizumab. **, p < 0.01; ***, p < 0.001, compared one month and three month data
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us